D
David S.H. Bell
Researcher at University of Alabama at Birmingham
Publications - 224
Citations - 9938
David S.H. Bell is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 43, co-authored 217 publications receiving 9212 citations. Previous affiliations of David S.H. Bell include GlaxoSmithKline & University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure A Consensus Statement From the American Heart Association and American Diabetes Association
Richard W. Nesto,David S.H. Bell,Robert O. Bonow,Vivian Fonseca,Scott M. Grundy,Edward S. Horton,Martin Le Winter,Daniel Porte,Clay F. Semenkovich,Sidney C. Smith,Lawrence H. Young,Richard Kahn +11 more
TL;DR: Because people with diabetes are at increased risk for CVD and many have preexisting heart disease, the edema that sometimes accompanies the use of a TZD can be cause for concern, as it may be a harbinger or sign of congestive heart failure (CHF).
Journal ArticleDOI
American association of clinical endocrinologists and american college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease
Paul S. Jellinger,Yehuda Handelsman,Paul D. Rosenblit,Zachary T. Bloomgarden,Vivian Fonseca,Alan J. Garber,George Grunberger,Chris K. Guerin,David S.H. Bell,Jeffrey I. Mechanick,Rachel Pessah-Pollack,Kathleen Wyne,Donald A. Smith,Eliot A. Brinton,Sergio Fazio,Michael H. Davidson,Farhad Zangeneh,Michael A. Bush +17 more
TL;DR: This CPG is a practical tool that endocrinologists, other health care professionals, health-related organizations, and regulatory bodies can use to reduce the risks and consequences of dyslipidemia.
Journal ArticleDOI
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
George L. Bakris,George L. Bakris,George L. Bakris,Vivian Fonseca,Vivian Fonseca,Richard E. Katholi,Richard E. Katholi,Janet B. McGill,Franz H. Messerli,Franz H. Messerli,Franz H. Messerli,Robert A. Phillips,Philip Raskin,Jackson T. Wright,Rosemary Oakes,Mary Ann Lukas,Karen M. Anderson,David S.H. Bell,David S.H. Bell +18 more
TL;DR: Use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension.
Journal ArticleDOI
Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?
TL;DR: A growing body of data suggests that low 25-hydroxyvitamin D levels may adversely affect cardiovascular health as discussed by the authors, and large randomized controlled trials are needed to firmly establish the relevance of vitamin D status to cardiovascular health.
Journal ArticleDOI
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association.
Richard W. Nesto,David S.H. Bell,Robert O. Bonow,Vivian Fonseca,Scott M. Grundy,Edward S. Horton,Martin Le Winter,Daniel Porte,Clay F. Semenkovich,Sidney C. Smith,Lawrence H. Young,Richard Kahn +11 more
TL;DR: Beneficial effects of TZDs on glycemia and cardiovascular risk factors have made them attractive agents in patients with type 2 diabetes who are at high risk for CVD, there is a growing recognition, however, that edema can occur in patients treated with either drug.